Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management to enhance the efficiency of fund usage while ensuring the normal operation of investment projects and the safety of the raised funds [1][5]. Group 1: Fund Management Overview - The company raised a total of RMB 897,999,976.34 through a non-public issuance of 31,420,573 shares at a price of RMB 28.58 per share, with a net amount of RMB 885,820,523.22 after deducting issuance costs [1]. - The current balance of the raised funds is RMB 201,103,541.25, with a portion remaining idle for a period [2]. Group 2: Cash Management Plan - The company intends to use up to RMB 210 million of the idle raised funds for cash management, investing in safe and liquid financial products such as structured deposits and large certificates of deposit [2][3]. - The cash management will be valid for 12 months from the approval date by the board of directors and the supervisory board [3]. Group 3: Decision-Making Process - The board of directors and the supervisory board have approved the cash management plan, which does not require shareholder meeting approval [3][5]. - The company has authorized its legal representative or designated personnel to make investment decisions within the specified limits [3]. Group 4: Impact and Benefits - The cash management is expected to improve fund utilization efficiency and enhance the overall performance of the company, providing better returns for shareholders [4][5]. - The company has established risk control measures to ensure that the cash management does not affect the normal operation of investment projects [4]. Group 5: Sponsor's Opinion - The sponsor, Huatai United Securities, has confirmed that the cash management plan complies with relevant regulations and does not harm the interests of the company or its shareholders, particularly minority shareholders [5][6].

Group 1 - The board of directors of the company held its 19th meeting of the 5th session on August 28, 2025, with all 9 directors present, ensuring the meeting's legality and effectiveness [1] - The board approved a proposal to manage temporarily idle raised funds of up to RMB 210 million in safe and liquid principal-protected financial products [2] - The company plans to manage temporarily idle self-owned funds of up to RMB 250 million to enhance the efficiency of fund utilization [2] Group 2 - The profit distribution plan proposes a cash dividend of RMB 2 per 10 shares (tax included), with an expected total cash dividend distribution of RMB 68,383,874.60 (tax included) based on the total share capital as of June 30, 2025 [3] - A wholly-owned subsidiary intends to acquire 4 "Meng Tuan" trademarks from Century Mengbang (Shanghai) Information Technology Co., Ltd. for RMB 10,000, which constitutes a related party transaction [3] - The company plans to rename its financial accounting department to the Financial Management Center to enhance financial management efficiency and strategic support [4]

Meeting Overview - The fifth meeting of the Supervisory Board of the company was held on August 28, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Financial Reporting - The 2025 semi-annual report was approved, confirming that its content and format comply with the regulations of the China Securities Regulatory Commission and the stock exchange, accurately reflecting the company's operational results and financial status [1][2]. - The report disclosed no false records, misleading statements, or significant omissions, and no violations of confidentiality by the personnel involved in its preparation were found [1]. Fund Management - The company confirmed that the use of raised funds complies with relevant regulations, with no changes in the purpose of the funds or harm to shareholder interests [2]. - The profit distribution plan for 2025 was deemed compliant and reasonable, ensuring the company's sustainable development while sharing profits with shareholders [2]. - The Supervisory Board approved the temporary use of up to 210 million yuan of idle raised funds for cash management, ensuring it would not affect normal business operations [3]. - Additionally, the company approved the use of 250 million yuan of idle self-owned funds for cash management under necessary approval procedures [3]. Related Transactions - The wholly-owned subsidiary, Luoyang Lepet Health Technology Co., Ltd., plans to acquire four "Meng Tuan" trademarks from Century Mengbang (Shanghai) Information Technology Co., Ltd. for 10,000 yuan, which aligns with the company's pet business development strategy and enhances brand competitiveness [4].

Group 1 - The company, Pulike Biological Engineering Co., Ltd., will hold its first extraordinary general meeting of shareholders in 2025 on September 16, 2025, at 14:00 [1][3] - The meeting will take place at the company's conference room located at No. 15, Zhenghe Road, Luolong District, Luoyang City, Henan Province [1][3] - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with voting available from 9:15 to 15:00 on the day of the meeting [1][4] Group 2 - The meeting will include non-cumulative voting proposals that have been approved by the company's board of directors on August 28, 2025 [2][3] - There are no related shareholders that need to abstain from voting [3] - Shareholders must complete voting for all proposals before submission [4][5] Group 3 - Shareholders registered by the close of trading on September 10, 2025, are eligible to attend the meeting [5] - The company will provide a reminder service for shareholders to ensure participation in the voting process [4][5] - Proxy representation is allowed, and specific documentation is required for attendance [5][6]

Core Viewpoint - The announcement from Pulaike indicates a change in the designated representative for the ongoing supervision of its non-public stock issuance, ensuring continuity in oversight responsibilities [1] Group 1 - Pulaike received a letter from Huatai United Securities regarding the replacement of the designated representative for the ongoing supervision of its non-public stock issuance [1] - Huatai United Securities was the sponsor for Pulaike's non-public stock issuance in 2021, originally appointing Zhen Qing and Zhang Ruosi as the supervising representatives [1] - Due to personal work changes, Zhang Ruosi is unable to continue in the role, and Han Feichong has been appointed to take over the responsibilities [1]

证券代码：603566 证券简称：普莱柯 公告编号：2025-037 普莱柯生物工程股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 普莱柯生物工程股份有限公司（以下简称"公司"）于近日收到华泰联合证 券有限责任公司（以下简称"华泰联合证券"）出具的《关于更换普莱柯生物工 程股份有限公司非公开发行股票持续督导保荐代表人的函》。华泰联合证券作为 公司 2021 年度非公开发行股票的保荐机构，原委派甄清先生和张若思先生作为 持续督导保荐代表人。现张若思先生因个人工作变动，不能继续担任持续督导期 的保荐代表人，为保证公司持续督导工作的有序进行，华泰联合证券现委派韩斐 冲先生（简历详见附件）接替张若思先生担任持续督导保荐代表人，继续履行持 续督导职责。 韩斐冲先生，现任华泰联合证券投资银行业务线总监，保荐代表人。曾参与 完成的项目包括：北玻股份、容百科技、设研院、隆华科技、长青集团、江阴银 行、佳沃股份等再融资项目，电科数字、王府井、天山铝业等重大资产重组项目， 在保荐业务执业过程中严格遵 ...

Market Overview - The animal health sector experienced a decline of 0.5% on August 29, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Individual Stock Performance - The top performer in the animal health sector was Qudongli (code: 838275), with a closing price of 11.87 and an increase of 7.23% [1] - Other notable gainers included Yongshun Biological (code: 839729) with a 1.34% increase and Ruipu Biological (code: 300119) with a 0.81% increase [1] - Conversely, *ST Lvkang (code: 002868) saw a significant decline of 3.24%, closing at 26.32 [2] Trading Volume and Capital Flow - The total net outflow of main funds in the animal health sector was 53.36 million yuan, while retail funds saw a net inflow of 29.48 million yuan [2] - The trading volume for Qudongli was 92,700 hands, with a transaction amount of 108 million yuan [1] Fund Flow Analysis - *ST Lvkang experienced a net outflow of 11.85 million yuan from main funds, representing a 24.27% net share [3] - In contrast, retail funds for *ST Lvkang saw a net inflow of 7.44 million yuan, accounting for 15.25% of its total [3] - Other companies like Shenglian Biological and Zhongmu Co. also faced net outflows from main funds, indicating a trend of capital withdrawal in the sector [3]

Group 1 - The company, Pulaike (SH 603566), held its 19th meeting of the 5th board of directors on August 28, 2025, to review the proposal for the full and summary report of the 2025 semi-annual report [1] - For the year 2024, the company's revenue composition is as follows: veterinary biological products account for 96.44%, functional health products account for 1.79%, income from technology licensing or transfer accounts for 0.94%, and other businesses account for 0.83% [1]

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., has announced the use of part of its idle raised funds for cash management to improve fund efficiency and ensure project safety while increasing investment returns [1][2]. Group 1: Fundraising and Management - The company has raised a total of 897,999,976.34 yuan through a non-public offering of 31,420,573 shares at a price of 28.58 yuan per share, with a net amount of 885,820,523.22 yuan after deducting issuance costs [1]. - As of June 30, 2025, the company has utilized 3,884,676.19 yuan of the raised funds, leaving a balance of 201,103,541.25 yuan [1]. Group 2: Cash Management Details - The investment purpose is to enhance the efficiency of idle raised funds, ensure project construction and fund safety, and increase investment returns [2]. - The investment limit is set at no more than 210 million yuan, allowing for single or cumulative rolling cash management within a one-year period [2]. - The funds will be sourced from temporarily idle raised funds and will be invested in low-risk, high-liquidity financial products such as structured deposits and large-denomination certificates of deposit [2]. Group 3: Decision-Making and Oversight - The investment decision does not require shareholder meeting approval and is authorized to the company's legal representative or their authorized personnel [2]. - The company has implemented several risk control measures, including pre-planning by the finance department, ongoing management, and post-tracking accounting [2]. - The supervisory board and independent directors have the authority to oversee and audit the cash management process, ensuring compliance with necessary legal procedures [3].

Core Viewpoint - The company has approved a plan to use up to 210 million yuan of temporarily idle raised funds for cash management, focusing on low-risk and highly liquid financial products [1] Group 1 - The decision was made during the 19th meeting of the fifth board of directors and the 13th meeting of the fifth supervisory board [1] - The investment will be concentrated in principal-protected financial products such as structured deposits and large-denomination certificates of deposit [1] - The resolution is valid for 12 months, allowing funds to be used on a rolling basis within the approved limit [1] Group 2 - The company emphasizes that the investment risks are controllable, although they may still be affected by market fluctuations [1]